A Randomized Trial of Atropine vs Patching for Treatment of Moderate Amblyopia

AR Medghalchi¹*, S Dalili²

¹Department of Ophthalmology, Amiralmomenin Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran ²Department of Pediatrics endocrinology, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran

Abstract

Background: amblyopia is a major cause of visual impairment in children. Our aim is to compare patching and atropine penalization for treatment of moderate amblyopia in 4-10 years old children.

Methods: During 2004-2007, in a randomized clinical trial, 120 patients aged 4-10 years old with moderate amblyopia in the range of 20/40 -20/100 were enrolled. Subjects randomized either to patch therapy or twice weekly atropine penalization in equal groups and were followed for 2 years. The success rate was defined as increment of 2 or more lines of visual acuity or final visual acuity of 20/25 or better.

Results: The visual acuity in amblyopic eye improved from base line to a mean of 3.8 lines in patching group and mean of 3.7 lines in atropine group at the end of follow up. The average visual acuity in both groups was 0.5 Log MAR acuity that increased to 0.18 in patching group and 0.2 in atropine group.

Conclusion: Twice weekly atropine penalization could improve visual acuity of a magnitude like to improvement provided by patching in treatment of moderate amblyopia in patients aged 4-10 years.

Keywords: Moderate amblyopia; Patch theraphy; Atropine penalization

Introduction

Amblyopia is the most common cause of monocular visual loss in children.¹ Patch and atropine penalization of the sound eye has been the mainstay of the sound eye.²⁻⁴ Simons *et al.*,⁵ reported that atropine therapy (one drop in a week) was a successful treatment as daily therapy. A pediatric eye disease investigation group⁶ reported that 2 hours patching improved the moderate to severe amblyopia in 3-7 years children. Pediatric Eye Disease Investigation Group reported that daily atropine or patching has similar improvement of moderate amblyopia.²⁻⁴ We conducted a randomized clinical trial to compare the success rate of atropine administration twice a week with 2

hours patching for treatment of moderate amblyopia.

Materials and Methods

This prospective randomized clinical trial was undertaken in 120 subjects. Patients with the following criteria were enrolled. 1. Age of 4-10 years, 2. Visual acuity (VA) in amblyopic eye between 20/40 and 20/100, 3. Difference of visual acuity between eyes of equal or more than 3 Log MAR, 4. Difference in refractive error between eyes of equal or more than 1 diopter for hyperopia and 1.5 diopter for astigmatism, 5. Wearing of optical correction for at least 4 weeks and 6. At least 2 years follow-up.

Informed consent was obtained from the subjects before treatment. Randomization was done on the patients records, the even number assigned to 3 hours patch therapy and odd numbers for those undergone penalization with 0.5% atropine twice a week. The number of subjects in each group was 60 patients.

^{*}Correspondence: Abdorreza Medghalchi, MD, Fellowship of Pediatric Ophthalmology and Strabismus, Department of Ophthalmology, Amiralmomenin Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran. Tel: +98-131-7222704, Fax: +98-131-7756898, e-mail: Rezamed1340@yahoo.com

Received: November 10, 2010

Accepted: February 26, 2011

Cycloplegic refraction was done with 0.5% cyclopentolate. Suitable glass was prescribed and after one month of wearing of glass, VA was checked with E chart (nidek projector) at initiation of treatment and at each visit.

Successful treatment was defined as 2 or more lines of improvement in VA or VA of 20/25 or better in amblyopic eye. Then final mean of VA or amblyopic eye and rate of successful treatment of both groups were evaluated with SPSS software (Version 16, Chicago, IL, USA). This study was approved by Ethics Committee of Guilan University of Medical Sciences.

Results

Between January 2004 and January 2007, 120 subjects entered this study. Sixty patients were assigned to patching group and the same assigned to penalization group. About 45% of patients were female and the remainders were male. The mean VA in patching and penalization groups at initiation of treatment were 0.46 and 0.45 Log MAR respectively. The pre-

treatment data of patients were summarized in Table 1.

Sixty subjects were enrolled including patching group, so that in patients with two lines acuity difference between eyes, 2 hours patch therapy was performed and in subjects with three or more lines difference, 3 hours patch therapy was started. The successful rate of treatment was about 76%. About 50% of patients achieved VA of 20/25 or more at the end of follow-up. The frequency of patients achieved special level of VA in both groups that was summarized in Table 2. The mean increment of visual from base line was 3.6 lines. About 35% of achieved stereo acuity of 400 second of arc at the end of follow-up. The VA and improvement at the end of two years were summarized in Table 2.

Sixty subjects received penalization with 0.5% atropine twice a week. During improvement of the VA, the penalization dose decreased to one drop weekly. The successful rate of treatment was about 74%. About 50% of patients achieved VA of 20/25 or more at the end of follow-up. About 30% of patients achieved stereoacuity of 400 second of arc at the end of follow-up.

Table 1: Pre treatment patients' data

		Total patients	Patching group	Penalization group
	Male	55%	54%	56%
Sex				
	Female	45%	46%	46%
	4-<6	50	26	24
Age	6-<8	50	24	26
	8-10	20	10	10
VA in am	blyopia			
Snellen	Log MAR			
20/100	0.7	15	8	7
20/80	0.6	17	8	9
20/60	0.48	31	15	16
20/50	0.4	25	13	12
20/40	0.3	32	16	16
Mean Log MAR		0.45	0.45	0.45
VA in so	und eye			
Snellen	Log MAR			
20/20	0	80	41	39
20/25	0.1	20	9	11
20/30	0.2	15	7 3	8 2
20/40	0.3	5	3	2
Amount o	of anisometropia			
1-<2	·			
2-<3		60	31	29
3-<4		30	15	15
4-<5		20	9	11
		10	5	5

Table 2: Frequency of patients developed specific level of vision at the end of two years

	Patching	Penalization	Total	
Number of patients	60	60	120	
VA				
Snellen Log MAR				
>20/100 <0.7	100%	100%	100%	
>20/80 <0.6	100%	100%	100%	
>20/60 <0.48	99%	97%	98%	
>20/50 <0.4	95%	93%	94%	
>20/40 <0.3	88%	88%	88%	
>20/30 <0.2	74%	76%	75%	
>20/25 <0.1	51%	49%	50%	
>20/20 0	25%	25%	25%	
Mean Log MAR	0.15	0.17	0.16	

Among 120 patients, VA test at the end of treatment in both groups was summarized. The successful rate of treatment was about 75%. About 50% of patients achieved VA of 20/25 or more at the end of follow-up. The frequency of patients achieved the special level of VA in both groups was summarized in Table 2.

Discussion

We compared the effects of patching and atropine penalization for treatment of moderate amblyopia in 120 subjects aged 4-10 years in a randomized clinical trial. The mean VA at the end of treatment was 0.18 Log MAR or 20/30 in both groups. The VA in amblyopic eye increased from base line to a mean of 3.8 lines in patching and 3.6 lines in penalization groups. There was no statistically significant difference between both groups. The successful rate of treatment in penalization and patching groups were 74% and 76% respectively. There was no significant difference between the 2 groups in mean of VA or line of improvement. About 35% of patching group and 30% of atropine group achieved stereoacuity of 400 second of arc at the end of follow-up. Pediatric Eve Disease Investigation Group³ in their randomized trial of atropine VS patching of moderate amblyopia reported that 51% of patching group and 49% of atropine

group achieved VA of 20/25 or better. Also at the end of follow-up, VA improved from base line to a mean of 3.7 lines in the patching and 3.6 lines in atropine group. PEDIG⁷ in a randomized trial of atropine VS patching for treatment of amblyopia for follow-up at age of 10 years showed that patching and penalization with atropine resulted in a comparable improvement in VA of amblyopic eye. Their reports were like our results. PEDIG² in another study showed that visual acuity improved in both groups from base line 3.16 lines in patch group and 2.84 lines in atropine group. The success rates of treatment were 79% in patching group and 74% in atropine group. Simons⁵ reported that atropine treatment may produce better binocular function than patching treatment.

Our study showed that patching treatment and penalization with atropine had the same therapeutic effect for treatment of moderate amblyopia in patients of 4-10 years old.

Acknowledgments

We thank the staff of Eye Research Center of Guilan University of Medical Sciences for their help in this study.

Conflict of interest: None declared.

References

- Attebo K, Mitchell P, Cumming R, Smith W, Jolly N, Sparkes R. Prevalence and causes of amblyopia in an adult population. Ophthalmol-
- ogy 1998;**105**:154-9. [9442792] [http://dx.doi.org/10.1016/S0161-6420(98)91862-0]
- A randomized trial of atropine vs.
- Patching for treatment of moderate amblyopia in children. *Arch Ophthalmol* 2002;**120**:268-78. [11 879129]

- 3 Repka MX, Wallace DK, Beck RW, Kraker RT, Birch EE, Cotter SA, Donahue S, Everett DF, Hertle RW, Holmes JM, Quinn GE, Scheiman MM, Weakley DR; Pediatric Eye Disease Investigator Group. Two-year follow-up of a 6-month randomized trial of atropine vs patching for treatment of moderate amblyopia in children. Arch Ophthalmol 2005;123:149-57. [157 10809] [http://dx.doi.org/10.1001/archopht.123.2.149]
- 4 Repka MX, Cotter SA, Beck RW, Kraker RT, Birch EE, Everett DF, Hertle RW, Holmes JM, Quinn GE, Sala NA, Scheiman MM, Stager DR
- Sr, Wallace DK; Pediatric Eye Disease Investigator Group. A randomized trial of atropine regimens for treatment of moderate amblyopia in children. Ophthalmology 2004;111: 2076-85. [15522375] [http://dx.doi.org/10.1016/j.ophtha.2004.04.032]
- Simons K, Gotzler KC, Vitale S. Penalization versus part-time occlusion and binocular outcome in treatment of strabismic amblyopia. Ophthalmology 1997;104:21 56-60. [9400778]
- 6 Repka MX, Beck RW, Holmes JM, Birch EE, Chandler DL, Cotter SA, Hertle RW, Kraker RT, Moke PS, Quinn GE, Scheiman MM; Pediatric
- Eye Disease Investigator Group. A randomized trial of patching regimens for treatment of moderate amblyopia in children. *Arch Ophthalmol* 2003;**121**:603-11. [1274283] [http://dx.doi.org/10.1001/archopht.121.5.603]
- 7 Pediatric Eye Disease Investigator Group, Repka MX, Kraker RT, Beck RW, Holmes JM, Cotter SA, Birch EE, Astle WF, Chandler DL, Felius J, Arnold RW, Tien DR, Glaser SR. A randomized trial of atropine vs patching for treatment of moderate amblyopia: follow-up at age 10 years. Arch Ophthalmol 2008;126: 1039-44. [18695096]